Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

tical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus has nominated RG-101 for the treatment of HCV as a candidate for clinical development and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with financial estimates, the projected sufficiency of Regulus' capital position for future periods, the expected ability of Regulus to undertake certain activities and accomplish certain goals, the projected timeline of clinical development activities, and expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-look
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
3. Regulus to Present at Future Leaders in the Biotech Industry Conference
4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
7. Regulus to Present at Two Upcoming Investor Conferences
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... July 27 Timothy Mastro,MD, FACP, DTM&H, who ... Senior Director of Research, will share information on ... at the,International AIDS Conference in Mexico City., ... Trials," will examine ongoing and upcoming clinical trials ...
... advance the company,s clinical development programs and ... CombiPlex(TM) technology ... privately held pharmaceutical company developing novel,products based on proven ... excess of $22.5 million in a Series C private,equity ...
Cached Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 3
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... early stage breast cancer patients who undergo chemotherapy and/or ... eventually develop leukemia as a result of their treatment, ... a review of more than 20,000 breast cancer cases ... the risk for developing treatment-related leukemia, though low, is ... frequency of bone marrow cancers such as leukemia is ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... a Brown Medical School professor and Rhode Island Department ... is linked to fussy babies.//, ,Pamela High, ... at Brown Medical School and director of developmental-behavioural paediatrics ... Island Department of Health's Division of Family Health team, ...
... Minister of state for Industry Ashwini Kumar speaking at a ... the corporate sector in India to draw up a framework ... It is only then can the physically challenged be ... , The government's commitment towards the community is unflinching ...
... seasons? An exhaustive study on suicide has revealed that suicidal ... summer//. ,Researchers analyzed some 26,915 suicides that ... revealed that those born in the summer and spring seasons, ... to attempt suicide. This tendency was more pronounced amongst women, ...
... several young men treat their erection problems with erectile ... These results were revealed after an anonymous survey of ... ,The research was led by Najah Senno Musacchio, ... results were presented in San Francisco, at the Pediatric ...
... on Saturday that she would lift her surveillance zone for ... a dead swan// was found to have the lethal H5N1 ... at stopping the spread of the deadly bird flu virus ... restrictions were imposed after finding the highly pathogenic H5N1 virus ...
... and action against smoking in Scotland, it would stop sales of ... buy it. ,Ministers have not decided whether to back ... McConnell's determination to reduce smoking rates in Scotland. ,In ... and a member of the expert group, "Smoking is far worse ...
Cached Medicine News:Health News:Minister Of State For Industry Urges Corporate Sectors To Help India's Disabled Population 2Health News:Young Men Treating Erection Problems without Doctors Prescription 2
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
Medicine Products: